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doi:10.1016/j.ijid.2006.09.012Figure 1 Axial, FLAIR image demonstrates diffuse, ill-defined
hyperintense areas in the periventricular white matter, without
significant mass effect.A case of human immunodeficiency virus infec-
tion disclosed by cytomegalovirus encephalitis
We report herein an unusual case of human immunodefi-
ciency virus (HIV) infection disclosed by hypothalamic ame-
norrhea and cytomegalovirus (CMV) encephalitis.
One year before admission the patient presented with
amenorrhea, mild gait unsteadiness, anorexia, easy fatig-
ability andweight loss (10 kg). Eight months before admission
she had visited a gynecologist who prescribed hormonal
therapy for amenorrhea, without any effect. Laboratory tests
performed at the time showed anemia with increased serum
ferritin. At the same time, the patient visited a psychiatrist,
who prescribed an antidepressant. Due to the unresponsive-
ness of the patient’s symptoms to the antidepressant treat-
ment, a head CTscan was performed, which was normal. The
patient was admitted to the endocrinology department for
investigation of amenorrhea.
Hormonal evaluation on admission showed normal serum
luteinizing hormone (LH: 2.18 mIU/ml) and follicle-stimulat-
ing hormone (FSH: 2.69 mIU/ml) concentrations, and an
exaggerated LH (40.93 mIU/ml) and FSH (24.93 mIU/ml)
activity after gonadotropin-releasing hormone (GnRH)
administration.
The patient was diagnosed as having hypothalamic ame-
norrhea and hormonal replacement therapy was prescribed.
On neurological examination the patient was alert, but had a
low score (23/30) onmini-mental status examination (MMSE).
She presented involuntary choreiform movements of the
upper and lower extremities and was unable to perform
the tandem walking test. She presented dysdiadochokinesia
and the deep tendon reflexes were symmetrically increased.
A magnetic resonance imaging (MRI) examination of the brain
was performed and demonstrated diffuse hyperintense areas
on T2-weighted sequences in the periventricular white mat-ter, as well as in the centrum semiovale bilaterally. The
abnormal areas were located mainly in the occipital lobes
and there was no evidence of mass effect or contrast
enhancement (Figure 1); the patient refused any further
investigation and she was discharged.
Three months later she was re-admitted to the neurology
department due to deteriorating gait unsteadiness. Her MMSE
374 Letters to the Editorscore had further deteriorated (19/30). She tested positive for
HIV-1 infectionwith a lowCD4+ cell count (42/mm3) and anHIV
viral load of 105 400 copies of RNA per milliliter of plasma. A
lumbar puncture was performed and PCR examination of
cerebrospinal fluid (CSF) tested positive for CMV infection.
Thepatientwas commencedonganciclovir—foscarnet for CMV
encephalitis and highly active antiretroviral therapy (HAART)
including zidovudine, lamivudine and ritonavir—lopinavir for
HIV infection.
Six months later there was a significant improvement in
her cognitive (MMSE: 25) and neurological symptoms fol-
lowed by resumption of menses. A substantial CD4+ T-cell
recovery (142/mm3) and viral load fewer than 50 copies of
RNA per milliliter was also observed. At the follow-up MRI
scan 6 months post-treatment, there was almost complete
resolution of the ill-defined hyperintense areas in the peri-
ventricular area (Figure 2). The patient continues to attend
the HIV outpatient clinic at our hospital; she is feeling much
better and continues to receive HAART and valganciclovir as
maintenance therapy for CMV and HIV infection.
There is little information relating to sex hormones in HIV-
infectedwomen. However, a disorder ofmenstrual function by
some viral effect on the pituitary—gonadal axis that includes
anovulatory cycles seems to exist. Functional or hypothalamic
amenorrhea is an uncommon manifestation in HIV-infected
women and occurs when these patients have a low CD4+ count
(<50/mm3).1—4 High viral load has also been associated with
cycle variability although there are studies that do not show
any association.3 The exact etiology of functional or hypotha-
lamic amenorrhea is unknown, and remains a diagnosis of
exclusion. The common feature is a reduction in the activity
of the GnRH neurons in the hypothalamus, leading to a corre-
sponding reduction in secretion of FSH and LH.4
CMV neurological disease is also an uncommon life-threa-
tening complication of patients with HIV infection, mainlyFigure 2 Follow-up MRI examination, 6 months post-treat-
ment. Coronal, FLAIR image where there is no evidence of
abnormality in the periventricular area.those with a low CD4+ T-cell count.5—8 CMV neurological
disease causes dementia, encephalitis (as in our patient),
and ascending polyradiculopathy.5—8,9,10
The symptoms of encephalitis are determined by the
anatomic location involved. In patients with CMVencephalitis
characterized by microglial nodules or focal parenchymal
necrosis, the most prominent clinical feature is dementia,
while in patients with CMV ventriculoencephalitis the disease
has a more acute course and is characterized by lethargy,
confusion, and cranial nerve palsies.9 The prognosis is poor
and death occurs within weeks of diagnosis in untreated
patients.9,10
Although MRI can be suggestive of the central nervous
system disease, diagnosis should be made using PCR detec-
tion of viral DNA in the CSF as in our patient.6,10 The
diagnostic reliability of the PCR method is high, as it has
been evaluated by comparing its data with histopathological
observations at autopsy, virus isolation from CSF and clinical
findings; the sensitivity has been found to be greater than 80%
and the specificity greater than 90%.10
The treatment of CMV nervous system disease is based
only on a few case reports and consists of a combination of
ganciclovir and foscarnet therapy, which seems to be the
most effective treatment.6,10 Our patient improved by the
second week of ganciclovir and foscarnet treatment. She
received HAART that could modify the course of the disease
by enhancement of her immune system.
In conclusion we believe that it is important to consider
HIV infection in patients with neurological deficits even if
they do not belong to any identifiable high risk group, as
timely treatment can lead to significant improvement and
save the patient’s life.
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